Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

NCT01024946 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
11
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators